Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02602860 · ClinicalTrials.gov registry record · Phase 1
A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
A Phase 1 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02602860 is a Phase 1 study that has completed, run by UCB Pharma. The registered enrollment target is 13 participants.
The verdict
NCT02602860, a Phase 1 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study will estimate how fast two antiepileptic drugs (Levetiracetam and Brivaracetam) enter the human brain. Brain imaging will be used to measure how quickly the radioactive probe \[11C\]UCB-J exits the brain when Levetiracetam or Brivaracetam are given. This will be used to estimate how fast the antiepileptic drugs enter the brain.
Interventions
- DRUG Levetiracetam
- DRUG Brivaracetam
- RADIATION [11C]UCB-J
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02602860
The ClinicalTrials.gov registry entry for NCT02602860 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Levetiracetam is the first listed.
NCT02602860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02602860 about?
NCT02602860 is a clinical study titled "A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers". This study will estimate how fast two antiepileptic drugs (Levetiracetam and Brivaracetam) enter the human brain. Brain imaging will be used to measure how quickly the radioactive probe \[11C\]UCB-J exits the brain when Levetiracetam or Brivaracetam are given. This will be used to estimate how fast ...
What is the current status of trial NCT02602860?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-11. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02602860?
The interventions under investigation include: Levetiracetam (DRUG), Brivaracetam (DRUG), [11C]UCB-J (RADIATION).
Who is sponsoring clinical trial NCT02602860?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.